[HTML][HTML] Prediction of drug synergism between peptides and antineoplastic drugs Paclitaxel, 5-Fluorouracil, and Doxorubicin using in silico approaches
N Vale, M Pereira, J Santos, C Moura… - International Journal of …, 2022 - mdpi.com
Chemotherapy is the main treatment for most early-stage cancers; nevertheless, its efficacy
is usually limited by drug resistance, toxicity, and tumor heterogeneity. Cell-penetrating …
is usually limited by drug resistance, toxicity, and tumor heterogeneity. Cell-penetrating …
Prediction of Drug Synergism between Peptides and Antineoplastic Drugs Paclitaxel, 5-Fluorouracil, and Doxorubicin Using In Silico Approaches
N Vale, M Pereira, J Santos… - International …, 2022 - pubmed.ncbi.nlm.nih.gov
Chemotherapy is the main treatment for most early-stage cancers; nevertheless, its efficacy
is usually limited by drug resistance, toxicity, and tumor heterogeneity. Cell-penetrating …
is usually limited by drug resistance, toxicity, and tumor heterogeneity. Cell-penetrating …
Prediction of Drug Synergism between Peptides and Antineoplastic Drugs Paclitaxel, 5-Fluorouracil, and Doxorubicin Using In Silico Approaches
N Vale, M Pereira, J Santos, C Moura, L Marques… - IJMS, 2022 - agris.fao.org
Chemotherapy is the main treatment for most early-stage cancers: nevertheless, its efficacy
is usually limited by drug resistance, toxicity, and tumor heterogeneity. Cell-penetrating …
is usually limited by drug resistance, toxicity, and tumor heterogeneity. Cell-penetrating …
[HTML][HTML] Prediction of Drug Synergism between Peptides and Antineoplastic Drugs Paclitaxel, 5-Fluorouracil, and Doxorubicin Using In Silico Approaches
N Vale, M Pereira, J Santos, C Moura… - … Journal of Molecular …, 2023 - ncbi.nlm.nih.gov
Chemotherapy is the main treatment for most early-stage cancers; nevertheless, its efficacy
is usually limited by drug resistance, toxicity, and tumor heterogeneity. Cell-penetrating …
is usually limited by drug resistance, toxicity, and tumor heterogeneity. Cell-penetrating …
Prediction of Drug Synergism between Peptides and Antineoplastic Drugs Paclitaxel, 5-Fluorouracil, and Doxorubicin Using In Silico Approaches
N Vale, M Pereira, J Santos, C Moura… - … Journal of Molecular …, 2022 - europepmc.org
Chemotherapy is the main treatment for most early-stage cancers; nevertheless, its efficacy
is usually limited by drug resistance, toxicity, and tumor heterogeneity. Cell-penetrating …
is usually limited by drug resistance, toxicity, and tumor heterogeneity. Cell-penetrating …
Prediction of Drug Synergism between Peptides and Antineoplastic Drugs Paclitaxel, 5-Fluorouracil, and Doxorubicin Using In Silico Approaches.
N Vale, M Pereira, J Santos, C Moura… - International …, 2023 - search.ebscohost.com
Chemotherapy is the main treatment for most early-stage cancers; nevertheless, its efficacy
is usually limited by drug resistance, toxicity, and tumor heterogeneity. Cell-penetrating …
is usually limited by drug resistance, toxicity, and tumor heterogeneity. Cell-penetrating …
Prediction of Drug Synergism between Peptides and Antineoplastic Drugs Paclitaxel, 5-Fluorouracil, and Doxorubicin Using In Silico Approaches.
N Vale, M Pereira, J Santos, C Moura… - … Journal of Molecular …, 2022 - europepmc.org
Chemotherapy is the main treatment for most early-stage cancers; nevertheless, its efficacy
is usually limited by drug resistance, toxicity, and tumor heterogeneity. Cell-penetrating …
is usually limited by drug resistance, toxicity, and tumor heterogeneity. Cell-penetrating …